Bento, L, Gutiérrez, A, Martinez, C, Verdet, MCO, Sorribes, M, Caballero, AC, Peña, M, Pérez, A, Jiménez-Ubieto, A, Medina, L, Bastos-Oreiro, M, Caldas-González, PF, Navarro, B, Salcedo, I, Abrisqueta, P, Español, I, Cornago, J, Martín-Moro, F, García, L, Gómez, P, Varela, MR, Puente, M, Zanabili, J, Zudaire, T, Zeberio, I, del Campo, R, González, L, González, P, Blázquez, C, Rovira, J, Sitges, M, Franch-Sarto, M, Cabero, A, Mussetti, A, Montoro, J, Sampol, A, Sureda, A, Caballero, D, García-Sancho, AM. Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study. Blood Advances. 2025; 9(13)DOI:10.1182/bloodadvances.2024015415. PMID:40163764. IF:7.100(Q1/2D).

Rubio, MA, Cisa-Wieczorek, S, Mozos, A, Castellet, H, Bussaglia, E, Carricondo, M, Hernández-Alvarez, MI, Sierra, J, Nomdedéu, JF. SGK1 repression by WT1 may confer a survival advantage to leukemic cells under stress conditions. ANNALS OF HEMATOLOGY. 2025; 104(7)DOI:10.1007/s00277-025-06458-z. PMID:40613901. IF:2.400(Q2/5D).

Moreno, DF, Oriol, A, de la Rubia, J, Hernández, MT, Iñigo, MB, Palomera, L, de Arriba, F, González, Y, Teruel, AI, Pardo, JL, de la Guía, AL, Sampol, A, Ríos-Tamayo, R, Sureda, A, Gutiérrez, NC, Calasanz, MJ, Ramos, MLM, Mateos, MV, San Miguel, J, Lahuerta, JJ, Bladé, J, Rosiñol, L. Is t(11;14) Always aStandard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Trials. Clinical Lymphoma Myeloma & Leukemia. 2025; 25(7)DOI:10.1016/j.clml.2025.01.014. PMID:39955256. IF:2.700(Q2/4D).

Gagelmann, N, de Witte, M, Peczynski, C, Boreland, W, Broers, AEC, Jost, E, Kulagin, A, Esquirol, A, Sica, S, Kuball, J, Errico, G, Bethge, W, Maertens, J, Stölzel, F, Forcade, E, Collin, M, Parma, M, Choi, G, Kröger, N, Di Chio, MC, Finazzi, MC, Corral, LL, Rifón, J, Mussetti, A, Bloor, A, Ladetto, M, Schoemans, H, Penack, O, Moiseev, I, Peric, Z. Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party. Blood Cancer Journal. 2025; 15(1)DOI:10.1038/s41408-025-01315-8. PMID:40467580. IF:11.600(Q1/1D).

Jiménez-Vicente, C, Arribas, I, Pomares, H, Ramil, G, Castaño-Diez, S, Pérez-Valencia, AI, Sturla, AL, López-Guerra, M, Martinez-Roca, A, Zugasti, I, Guijarro, F, Cortés-Bullich, A, Merchán, B, Triguero, A, Monge, I, Tuca, A, Oñate, G, Garrido, A, Sierra, J, Arnan, M, Esteve, J, Díaz-Beyá, M. Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia. HAEMATOLOGICA. 2025; 110(6)DOI:10.3324/haematol.2024.286589. PMID:39844754. IF:10.100(Q1/2D).

Jimenez-Vicente, C, Cardus, A, Castaño-Diez, S, Ramil, G, Garcia-Avila, S, Gomez-Perez, L, Esteban, D, Arribas, I, Sturla, AL, Lopez-Guerra, M, Martinez-Roca, A, Cortes-Bullich, A, Perez-Valencia, AI, Zugasti, I, Monge, I, Carcelero, E, Vall-Llovera, F, Vives, S, Sierra, J, Nomdedeu, J, Oñate, G, Garrido, A, Pratcorona, M, Pomares, H, Arnan, M, Guijarro, F, Diaz-Beya, M, Esteve, J. Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations. Blood Cancer Journal. 2025; 15(1)DOI:10.1038/s41408-025-01298-6. PMID:40368916. IF:11.600(Q1/1D).